广泛性焦虑障碍血浆神经肽Y、P物质水平及相关因素分析
|
摘要
目的探讨广泛性焦虑障碍(generalized anxiety disorder,GAD)患者发病期血浆神经肽Y(neuropeptide Y,NPY)及P物质(substance P,SP)水平及其相关影响因素。方法采用酶联免疫吸附法测定50例GAD患者(GAD组)和48例健康者(正常对照组)的血浆NPY、SP水平。采用汉密尔顿抑郁量表-17项(17-item Hamilton rating scale for depression,HAMD-17)、汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)评估患者的临床症状。结果与正常对照组比较,GAD组的血浆NPY水平降低[(5.04±1.45)μg/mL vs(8.27±2.18)μg/mL,P<0.01],SP水平升高[(7.24±2.17)μg/mL vs(5.38±1.94)μg/mL,P<0.01];NPY水平与HAMA总分呈负相关(r=-0.41,P=0.03),SP水平与HAMA总分呈正相关(r=0.58,P=0.02)。结论 GAD患者可能存在外周NPY能及SP能神经元功能紊乱。
引文
[1] Kroenke K,Spitzer RL,Williams JB,et al.Anxiety disorders in primary care:prevalence,impairment,comorbidity,and detection[J].Ann Intern Med,2007,146(5):317-325.
[2] Reichmann F,Holzer P.Neuropeptide Y:A stressful review[J].Neuropeptides,2016,55:99-109.
[3] Longo A,Mele P,Bertocchi I,et al.Conditional inactivation of neuropeptide Y Y1 receptors unravels the role of Y1 and Y5 receptors coexpressing neurons in anxiety[J].Biol Psychiatry,2014,76(11):840-849.
[4] Yang LM,Yu L,Jin HJ,et al.Substance P receptor antagonist in lateral habenula improves rat depression-like behavior[J].Brain Res Bull,2014,100(1):22-28.
[5] Amstadter AB,Koenen KC,Ruggiero KJ,et al.NPY Moderates the Relation between Hurricane Exposure and Generalized Anxiety Disorder in an Epidemiologic Sample of Hurricane-Exposed Adults[J].Depress Anxiety,2010,27(3):270-275.
[6] Bannon AW,Seda J,Carmouche M,et al.Behavioral characterization of neuropeptide Y knockout mice[J].Brain Res,2000,868(1):79-87.
[7] Sudakov SK,Medvedeva OF,Rusakova IV,et al.Differences in genetic predisposition to high anxiety in two inbred rat strains:role of substance P,diazepam binding inhibitor fragment and neuropeptide Y[J].Psychopharmacol,2001,154(4):327-335.
[8] Sabban EL,Serova LI,Alaluf LG,et al.Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress[J].Behav Brain Res,2015,295:9-16.
[9] Ide S,Hara T,Ohno A,et al.Opposing roles of corticotropin-releasing factor and neuropeptide Y within the dorsolateral bed nucleus of the stria terminalis in the negative affective component of pain in rats[J].J Neurosci,2013,33(14):5881-5894.
[10] Christiansen SH,Olesen MV,G?tzsche CR,et al.Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice[J].Neuropeptides,2014,48(6):335-344.
[11] Mello DM,Marcinichen DR,Madruga D,et al.Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P[J].Behav Brain Res,2007,181(2):232-238.
[12] Ebner K,Singewald N.The role of substance P in stress and anxiety responses[J].Amino Acids,2006,31(3):251-272.
[13] Domschke K,Hohoff C,Jacob C,et al.Chromosome 4q31-34 panic disorder risk locus:Association of neuropeptide Y Y5 receptor variants[J].Am J Med Genet B Neuropsychiatr Genet,2010,147B(4):510-516.
[14] Boulenger JP,Jerabek I,Jolicoeur FB,et al.Elevated plasma levels of neuropeptide Y in patients with panic disorder[J].Am J Psychiatry,1996,153(1):114-116.
[15] Kramer MS,Cutler N,Feighner J,et al.Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors[J].Science,1998,281(5383):1640-1645.
[16] Nikischa G.CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy[J].Eur Psychiatry,2008,23(5):356-359.
[2] Reichmann F,Holzer P.Neuropeptide Y:A stressful review[J].Neuropeptides,2016,55:99-109.
[3] Longo A,Mele P,Bertocchi I,et al.Conditional inactivation of neuropeptide Y Y1 receptors unravels the role of Y1 and Y5 receptors coexpressing neurons in anxiety[J].Biol Psychiatry,2014,76(11):840-849.
[4] Yang LM,Yu L,Jin HJ,et al.Substance P receptor antagonist in lateral habenula improves rat depression-like behavior[J].Brain Res Bull,2014,100(1):22-28.
[5] Amstadter AB,Koenen KC,Ruggiero KJ,et al.NPY Moderates the Relation between Hurricane Exposure and Generalized Anxiety Disorder in an Epidemiologic Sample of Hurricane-Exposed Adults[J].Depress Anxiety,2010,27(3):270-275.
[6] Bannon AW,Seda J,Carmouche M,et al.Behavioral characterization of neuropeptide Y knockout mice[J].Brain Res,2000,868(1):79-87.
[7] Sudakov SK,Medvedeva OF,Rusakova IV,et al.Differences in genetic predisposition to high anxiety in two inbred rat strains:role of substance P,diazepam binding inhibitor fragment and neuropeptide Y[J].Psychopharmacol,2001,154(4):327-335.
[8] Sabban EL,Serova LI,Alaluf LG,et al.Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress[J].Behav Brain Res,2015,295:9-16.
[9] Ide S,Hara T,Ohno A,et al.Opposing roles of corticotropin-releasing factor and neuropeptide Y within the dorsolateral bed nucleus of the stria terminalis in the negative affective component of pain in rats[J].J Neurosci,2013,33(14):5881-5894.
[10] Christiansen SH,Olesen MV,G?tzsche CR,et al.Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice[J].Neuropeptides,2014,48(6):335-344.
[11] Mello DM,Marcinichen DR,Madruga D,et al.Involvement of NK1 receptors in metabolic stress markers after the central administration of substance P[J].Behav Brain Res,2007,181(2):232-238.
[12] Ebner K,Singewald N.The role of substance P in stress and anxiety responses[J].Amino Acids,2006,31(3):251-272.
[13] Domschke K,Hohoff C,Jacob C,et al.Chromosome 4q31-34 panic disorder risk locus:Association of neuropeptide Y Y5 receptor variants[J].Am J Med Genet B Neuropsychiatr Genet,2010,147B(4):510-516.
[14] Boulenger JP,Jerabek I,Jolicoeur FB,et al.Elevated plasma levels of neuropeptide Y in patients with panic disorder[J].Am J Psychiatry,1996,153(1):114-116.
[15] Kramer MS,Cutler N,Feighner J,et al.Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors[J].Science,1998,281(5383):1640-1645.
[16] Nikischa G.CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy[J].Eur Psychiatry,2008,23(5):356-359.